Follow

FluoGuide A/S - Flagging message

01 June 2021 - 13:23

Copenhagen, Denmark, 1 June 2021

FluoGuide A/S (“FluoGuide” or “the Company”) hereby announce that Arbejdernes Landsbank has informed the Company that they have 581.604 shares which corresponds to 5,14 percent of all shares in the Company.

For further information, please contact:
Henrik Moltke
FluoGuide A/S
Phone: +45 22 44 54 04
E-mail: [email protected]

Certified Adviser:
Svensk Kapitalmarknadsgransking AB
Phone: +46 70 755 95 51
E-mail: [email protected]

About FluoGuide
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is conducting a proof-of-concept clinical study (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma. FluoGuide is listed on Nasdaq First North Sweden under the ticker “FLUO”.

Provided by: Cision
Nasdaq First North GM (Sweden)
FluoGuide A/S
FluoGuide A/S is a Denmark based company engaged in developing surgical solutions. Its technology includes uPAR which is a part of a proteolytic system and FG001 is a product injected into the patient's vein prior to surgery....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More